GB2556535A - A method for preparation of ibrutinib precursor - Google Patents
A method for preparation of ibrutinib precursor Download PDFInfo
- Publication number
- GB2556535A GB2556535A GB1800657.7A GB201800657A GB2556535A GB 2556535 A GB2556535 A GB 2556535A GB 201800657 A GB201800657 A GB 201800657A GB 2556535 A GB2556535 A GB 2556535A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ibrutinib
- precursor
- preparation
- pyrimidin
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A method for the preparation of ibrutinib's precursor, 3-(4-phenoxyphenyl)-1-((3R)-piperidin-3-il)-1H-pyrazolof [3,4-d]|pyrimidin-4-amine, involving arylation of N-protected 1-(piperidin-3-yl)pyrazolo[3,4-d]pyrimidin-4-amine in the presence of palladium catalyst, nitrogen-containing ligand, and base, with subsequent removal of the protecting groups by known methods, is reported. (Formula (II))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-15-98A LV15201B (en) | 2015-08-31 | 2015-08-31 | The method for the preparation of ibrutinib intermediate |
PCT/LV2015/000009 WO2017039425A1 (en) | 2015-08-31 | 2015-11-13 | A method for preparation of ibrutinib precursor |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201800657D0 GB201800657D0 (en) | 2018-02-28 |
GB2556535A true GB2556535A (en) | 2018-05-30 |
GB2556535B GB2556535B (en) | 2020-10-14 |
Family
ID=54754721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1800657.7A Active GB2556535B (en) | 2015-08-31 | 2015-11-13 | A method for preparation of ibrutinib precursor |
Country Status (4)
Country | Link |
---|---|
CA (1) | CA2987708C (en) |
GB (1) | GB2556535B (en) |
LV (1) | LV15201B (en) |
WO (1) | WO2017039425A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107674079B (en) * | 2017-09-27 | 2019-12-13 | 黑龙江珍宝岛药业股份有限公司 | Synthesis method of ibrutinib |
CN113200986A (en) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | Preparation method of ibrutinib intermediate |
CN114940678B (en) * | 2021-09-26 | 2023-02-07 | 上海贵之言医药科技有限公司 | Pyrazolopyrimidine ester compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2014139970A1 (en) * | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080007621A1 (en) | 2006-07-06 | 2008-01-10 | Sbc Knowledge Ventures, Lp | System and method of controlling access to an entrance |
MX2009010284A (en) | 2007-03-28 | 2010-01-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase. |
US20100331297A1 (en) | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | Heterocyclic tyrosine kinase inhibitors |
-
2015
- 2015-08-31 LV LVP-15-98A patent/LV15201B/en unknown
- 2015-11-13 GB GB1800657.7A patent/GB2556535B/en active Active
- 2015-11-13 WO PCT/LV2015/000009 patent/WO2017039425A1/en active Application Filing
- 2015-11-13 CA CA2987708A patent/CA2987708C/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2014139970A1 (en) * | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
Non-Patent Citations (1)
Title |
---|
European Journal of Organic Chemistry, vol. 2012, no. 36, 2012, A. Ben-Yahia et al., "Direct C-3 arylation sof 1H-indazoles", pp. 7075-7081. * |
Also Published As
Publication number | Publication date |
---|---|
WO2017039425A1 (en) | 2017-03-09 |
LV15201A (en) | 2017-03-20 |
CA2987708A1 (en) | 2017-03-09 |
CA2987708C (en) | 2022-08-02 |
GB201800657D0 (en) | 2018-02-28 |
GB2556535B (en) | 2020-10-14 |
LV15201B (en) | 2017-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196383A (en) | Benzo[B]Thiophene Compounds As Sting Agonists | |
UA111186C2 (en) | Methods and compositions for preparing noribogaine from voacangine | |
NZ704147A (en) | Partially saturated nitrogen-containing heterocyclic compound | |
PH12014501503A1 (en) | Purinone derivative hydrochloride | |
MY158257A (en) | Forms of rifaximin and uses thereof | |
IL237369B (en) | N-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3,-tetrafluoropropoxy)benzylamine in combination with an acetylcholinesterase inhibitor for treating alzheimer's disease | |
MY149705A (en) | Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof | |
MY167697A (en) | Method for producing 4,4-difluoro-3,4- dihydroisoquinoline derivatives | |
TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
EP2787082A4 (en) | Microorganism for simultaneously producing l-amino acid and riboflavin, and method for producing l-amino acid and riboflavin using same | |
EP2488559A4 (en) | Metal-neutralized sulfonated block copolymers, process for making them and their use | |
WO2012135047A3 (en) | Methods and compositions for preparing noribogaine from voacangine | |
EA201170753A1 (en) | NALMEPHENA HYDROCHLORIDE DIHYDRATE | |
CL2011001947A1 (en) | Compounds derived from substituted phenyl- {1,2,4} triazolo [1,5-a] pyridine-phenylamino, kinase inhibitors; Useful for treating disorders associated with vascular permeability. | |
MX368707B (en) | Method of inhibiting mutant c-kit. | |
EP2666797A4 (en) | Olefin block copolymer, and method for preparing same | |
GB2556535A (en) | A method for preparation of ibrutinib precursor | |
PH12015502751A1 (en) | Preparation of tert-butyl 4-((1r,2s,5r)-6- (benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.i]octane-2- carboxamido)piperidine-1-carboxylate | |
TN2012000258A1 (en) | Novel polymorphic shapes of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl)carbamate | |
IL233066B (en) | Method for synthesizing 1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridine-3-formamidine hydrochloride | |
PH12015500185A1 (en) | Azaheterocycles as bir2 and/or bir3 inhibitors | |
ZA201506483B (en) | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane | |
NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride | |
UA103197C2 (en) | Use of nifurtimox for the treatment of diseases caused by trichomonadida | |
NZ711328A (en) | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane |